Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Roger J Waltzman"'
Autor:
Michael J Newman, Jeffery A Nieves, Gary B Gordon, Diana L Hanna, Angela T Alistar, Mohammed NAl Hallak, Roger J Waltzman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/1066c9ece15f42a689682e4141b44383
Autor:
Eric T Williams, Roger J. Waltzman, Jack P. Higgins, Asis K. Sarkar, Aimee Iberg, Erin Willert
Publikováno v:
Cancer Research. 80:P1-18
Engineered toxin bodies (ETBs) are differentiated, targeted therapeutics comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLTA) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of actio
Autor:
David Peace, Amitabha Mazumder, Thomas Strack, Jason Tache, Deborah A. Katz, Roger J. Waltzman, Seung Tae Lee, Christine Burnett, Elizabeth Bay
Publikováno v:
Blood Cancer Discovery. 1:PO-63
Background: Engineered toxin bodies (ETBs) are a distinct class of targeted immunotoxins in development by Molecular Templates as anticancer therapeutics. ETBs have a novel mechanism of action that drives a potent and targeted response mediated by an
Autor:
Monica M. Mita, Shubham Pant, Emerson A. Lim, James Strauss, Renee Deehan, Narayan Lebaka, Erika Hamilton, Sohail F. Tavazoie, Oliver Rixe, Foster C. Gonsalves, Michael Szarek, Nimisha Schneider, Subhasree Sridhar, Roger J. Waltzman, Russell J. Schilder, David Martin Darst, Michael A. Postow, Kevin B. Kim, Syed Ahsan Raza, Alan Mita, Tomislav Dragovich, Igor Puzanov, Isabel Kurth, Bartosz Chmielowski, Joe Lin, Tobi Guennel, Robert Busby, Rebecca Redman, Eric K. Rowinsky, Gerald Steven Falchook, Celia Andreu, R. Donald Harvey, Robert Wasserman, Angela Jain, Masoud Tavazoie
Publikováno v:
Cancer Research. 80:LB-133
RGX-104, a first-in-class small-molecule LXR agonist modulates innate immunity and cancer progression via transcriptional activation of ApoE. ApoE protein suppresses tumor cell invasion and angiogenesis, and also depletes circulating and tumoral myel
Autor:
Tara Baetz, Mamia Zodelava, Christine Burnett, Vasile Musteata, Thomas Strack, Roger J. Waltzman, Tetiana Perekhrestenko, Sarah C. Wilson, Daniel O. Persky, Adolfo Enrique Diaz Duque, Troy H. Guthrie
Publikováno v:
Journal of Clinical Oncology. 38:TPS8074-TPS8074
TPS8074 Background: Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered form of Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains. ETBs work through novel mechanisms of action and are capable
Autor:
Frances Valdes, Valeria González, Brian A. Van Tine, Monica M. Mita, Christine Burnett, Thomas Strack, Zev A. Wainberg, Erika Hamilton, Banmeet Anand, Minal A. Barve, Andrew Brenner, Roger J. Waltzman, Joshua Pelham
Publikováno v:
Journal of Clinical Oncology. 38:e15567-e15567
e15567 Background: Engineered toxin bodies (ETBs), composed of a Shiga-like Toxin A subunit genetically fused to antibody-like binding domains, can force receptor internalization, self-route through intracellular compartments to the cytosol, and indu
Autor:
Roger J. Waltzman, Sara LeMar, Hilario J. Ramos, Garrett L. Robinson, Joseph D. Dekker, Brigitte Brieschke, Garrett L. Cornelison, Aimee T. Iberg, Asis K. Sarkar, Erin Willert, Jay Zhao
Publikováno v:
Journal of Clinical Oncology. 38:12-12
12 Background: Engineered toxin bodies (ETBs) comprised of a proprietarily engineered Shiga-like Toxin A subunit (SLT-A) genetically fused to antibody-like binding domains work through novel mechanisms of action and can force internalization, self-ro
Autor:
Jack T. Higgins, Roger J. Waltzman, Aimee T. Iberg, Asis K. Sarkar, Eric T Williams, Erin Willert
Publikováno v:
Journal of Clinical Oncology. 38:433-433
433 Background: Engineered toxin bodies (ETBs) are comprised of a proprietarily engineered Shiga-like Toxin A subunit genetically fused to antibody-like binding domains. MT-5111 is a de-immunized ETB targeting HER2 for solid tumors. MT-5111 works thr
Autor:
Richard Labotka, Yuhong Zhang, Divya Manoharan, Ajeeta B Dash, Erin Willert, Robert F. Cornell, Jack P. Higgins, Roger J. Waltzman, Michael J. Hanley, Jianchang Lin, Alexander Vorog, Ola Landgren, Morgan Leichter, Sikander Ailawadhi, Anya Lublinsky, Sean Ottinger, Shaji Kumar, John Newcomb
Publikováno v:
Blood. 134:1867-1867
Background CD38 is highly expressed on MM cells, hence anti-CD38 agents are of interest as a therapeutic approach in MM. The anti-CD38 monoclonal antibody, dara, as mono- or combination therapy, has substantially improved efficacy outcomes in RRMM, i
Autor:
Bernardo S. Reis, Elizabeth A. McMillan, Bartosz Chmielowski, Sohail F. Tavazoie, Monica M. Mita, Daniel Mucida, Antoni Ribas, Connie Zhao, Ilana Pollack, Masoud Tavazoie, Kimia N. Tafreshian, Alain C. Mita, Foster C. Gonsalves, Benjamin N. Ostendorf, Mark L. Derbyshire, Shugaku Takeda, Roger J. Waltzman, Raissa Tanqueco, Isabel Kurth, Eric K. Rowinsky, Michael Szarek, Jessica M. Posada, Celia Andreu-Agullo, Michael A. Postow
Publikováno v:
Cell, vol 172, iss 4
Therapeutic harnessing of adaptive immunity via checkpoint inhibition has transformed the treatment of many cancers. Despite unprecedented long-term responses, most patients do not respond to these therapies. Immunotherapy non-responders often harbor